In CRC, the targets of CAR-T-cell therapy include carcinoembryonic antigens (CEA), guanylyl cyclase C (GUCY2C), tumour-associated glycoprotein (TAG72) [144], epithelial cell adhesion molecule (EpCAM), NK cell surface receptor ligands (NKG2DLs) and six unique long 16 binding protein (UL-BP1-6) [60]. The gene discussed is CEACAM5; the disease is colorectal carcinoma.